Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

BioPorto

Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-

BioPorto

Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-

BioPorto

Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
2026 Q1 -tulosraportti
12 päivää sitten

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
6--
4--
6--
1--
1 763--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
20.8.
Menneet tapahtumat
2026 Q1 -tulosraportti
21.5.
2025 Q4 -tulosraportti
26.3.
2025 Q3 -tulosraportti
19.11.2025
2025 Q2 -tulosraportti
15.8.2025
2025 Q1 -tulosraportti
8.5.2025

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 11 t sitten
    ·
    11 t sitten
    ·
    We are excited to be part of the nephrology community at hashtag#ERA26 in Glasgow this week. With the updated KDIGO AKI/AKD guidelines currently in public review. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
    5 t sitten
    ·
    5 t sitten
    ·
    We know that KDIGO has issued their recommendations on each of the 18 topics. We are just waiting for the details. Now we need to put the spotlight on FDA. If they have no questions for the pre-application, and therefore give the green light for Bioporto to submit an application for the adult test. It will be interesting for us whether FDA will ensure that Bioporto receives breakthrough benefits. (just like they eventually got with the children's test) because KDIGO has given the NGAL test the strongest recommendation in some areas. If Bioporto is granted the breakthrough benefit, the following will happen. 1. Bioporto will be assigned some experts from FDA, which Bioporto can use if there are any questions. 2. They will receive quick feedback from FDA. 3. When the final application is complete and needs to be approved, it will be at the top of the pile. If Bioporto is granted the above benefit, it will be really fun to be a shareholder.
  • 1 päivä sitten
    ·
    1 päivä sitten
    ·
    There is really a lot of gold on the internet, you just have to bend down and pick it up. I have just found an overview of the topics that KDIGO's committee is currently in the process of agreeing on how the final document should be written. I have inserted a link where you can read about the different areas, What I am pleased about is that I have been right when I claimed that some areas will receive Grade 1 recommendations and others will receive lower ones. You can see that there are different color codes, which are the same colors used in the hospital world. If you click on the different topics, you can read about what diseases they are. So yes, they will be busy at Bioporto. Red: The absolute strongest recommendation (Grade 1) Blue: Strong recommendation (Grade 1 or strong Grade 2) Yellow: Minor or conditional recommendation (Grade 2) Green: Lowest recommendation / Baseline https://kdigo.org/guidelines/
    14 t sitten
    14 t sitten
    Tämä kommentti on poistettu.
    18 t sitten
    ·
    18 t sitten
    ·
    Unlike you, I have actually profited from BP. And it's probably only reasonable to ask questions, especially now that your years-long hype in BP has been completely and utterly totally misguided.
  • 1 päivä sitten
    1 päivä sitten
    Tämä julkaisu on poistettu.
    1 päivä sitten
    ·
    1 päivä sitten
    ·
    Hi 3D I have tried to do as you say. I'm getting into an almost 500-page report for the AKI area. It seems to be the one that is being prepared for publication. What's with the color codes? Once I have found the AKI report, then what?
    1 päivä sitten
    ·
    1 päivä sitten
    ·
    I have deleted this post and written a new one with a different link. try clicking the new link
  • 28.5.
    ·
    28.5.
    ·
    There must be someone who can explain "shorting" THOROUGHLY! How does it work in practice? Who offers it and why? Is there anything regarding TA, that "meets" shorting? And if so, how? Other explanations are also welcome..,: Many of us, it seems, don't have a grasp of shorting and everything it entails. Regards. Bagerbrød
    3 päivää sitten
    ·
    3 päivää sitten
    ·
    Likewise - we are still eagerly watching to see if today will push the stock up near 1.45! This is where the next "point" is, and the time interval between recent peaks COULD fit with today! I think today's closing price is exciting.
    3 päivää sitten
    ·
    3 päivää sitten
    ·
    yep - thanks 😊🐾
  • 28.5.
    ·
    28.5.
    ·
    Although it's nothing new, it's good that there are more and more small indicators of interest in the kidney area generally and Bioporto specifically. https://ugebrev.dk/life-science/bioporto-har-udviklet-et-produkt-mod-akut-nyreskade/
    3 päivää sitten · Muokattu
    ·
    3 päivää sitten · Muokattu
    ·
    Completely agree. The price has shot up 50% in 2 months and now seems to have found a natural level. No doubt many have taken that profit home, but that's actually what we want. That smaller short-term shareholders who bought under 1kr sell off, so that this group will increasingly get bigger and bigger gak. Now we will probably wait a week or 2 to get feedback from FDA regarding pre submission, and if it turns out positive as expected, then surely the price can crawl a bit higher. When/if KDIGO includes Ngal as a recommendation, then I don't think it will be unlikely we will go over 2kr.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q1 -tulosraportti
12 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 11 t sitten
    ·
    11 t sitten
    ·
    We are excited to be part of the nephrology community at hashtag#ERA26 in Glasgow this week. With the updated KDIGO AKI/AKD guidelines currently in public review. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
    5 t sitten
    ·
    5 t sitten
    ·
    We know that KDIGO has issued their recommendations on each of the 18 topics. We are just waiting for the details. Now we need to put the spotlight on FDA. If they have no questions for the pre-application, and therefore give the green light for Bioporto to submit an application for the adult test. It will be interesting for us whether FDA will ensure that Bioporto receives breakthrough benefits. (just like they eventually got with the children's test) because KDIGO has given the NGAL test the strongest recommendation in some areas. If Bioporto is granted the breakthrough benefit, the following will happen. 1. Bioporto will be assigned some experts from FDA, which Bioporto can use if there are any questions. 2. They will receive quick feedback from FDA. 3. When the final application is complete and needs to be approved, it will be at the top of the pile. If Bioporto is granted the above benefit, it will be really fun to be a shareholder.
  • 1 päivä sitten
    ·
    1 päivä sitten
    ·
    There is really a lot of gold on the internet, you just have to bend down and pick it up. I have just found an overview of the topics that KDIGO's committee is currently in the process of agreeing on how the final document should be written. I have inserted a link where you can read about the different areas, What I am pleased about is that I have been right when I claimed that some areas will receive Grade 1 recommendations and others will receive lower ones. You can see that there are different color codes, which are the same colors used in the hospital world. If you click on the different topics, you can read about what diseases they are. So yes, they will be busy at Bioporto. Red: The absolute strongest recommendation (Grade 1) Blue: Strong recommendation (Grade 1 or strong Grade 2) Yellow: Minor or conditional recommendation (Grade 2) Green: Lowest recommendation / Baseline https://kdigo.org/guidelines/
    14 t sitten
    14 t sitten
    Tämä kommentti on poistettu.
    18 t sitten
    ·
    18 t sitten
    ·
    Unlike you, I have actually profited from BP. And it's probably only reasonable to ask questions, especially now that your years-long hype in BP has been completely and utterly totally misguided.
  • 1 päivä sitten
    1 päivä sitten
    Tämä julkaisu on poistettu.
    1 päivä sitten
    ·
    1 päivä sitten
    ·
    Hi 3D I have tried to do as you say. I'm getting into an almost 500-page report for the AKI area. It seems to be the one that is being prepared for publication. What's with the color codes? Once I have found the AKI report, then what?
    1 päivä sitten
    ·
    1 päivä sitten
    ·
    I have deleted this post and written a new one with a different link. try clicking the new link
  • 28.5.
    ·
    28.5.
    ·
    There must be someone who can explain "shorting" THOROUGHLY! How does it work in practice? Who offers it and why? Is there anything regarding TA, that "meets" shorting? And if so, how? Other explanations are also welcome..,: Many of us, it seems, don't have a grasp of shorting and everything it entails. Regards. Bagerbrød
    3 päivää sitten
    ·
    3 päivää sitten
    ·
    Likewise - we are still eagerly watching to see if today will push the stock up near 1.45! This is where the next "point" is, and the time interval between recent peaks COULD fit with today! I think today's closing price is exciting.
    3 päivää sitten
    ·
    3 päivää sitten
    ·
    yep - thanks 😊🐾
  • 28.5.
    ·
    28.5.
    ·
    Although it's nothing new, it's good that there are more and more small indicators of interest in the kidney area generally and Bioporto specifically. https://ugebrev.dk/life-science/bioporto-har-udviklet-et-produkt-mod-akut-nyreskade/
    3 päivää sitten · Muokattu
    ·
    3 päivää sitten · Muokattu
    ·
    Completely agree. The price has shot up 50% in 2 months and now seems to have found a natural level. No doubt many have taken that profit home, but that's actually what we want. That smaller short-term shareholders who bought under 1kr sell off, so that this group will increasingly get bigger and bigger gak. Now we will probably wait a week or 2 to get feedback from FDA regarding pre submission, and if it turns out positive as expected, then surely the price can crawl a bit higher. When/if KDIGO includes Ngal as a recommendation, then I don't think it will be unlikely we will go over 2kr.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
6--
4--
6--
1--
1 763--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
20.8.
Menneet tapahtumat
2026 Q1 -tulosraportti
21.5.
2025 Q4 -tulosraportti
26.3.
2025 Q3 -tulosraportti
19.11.2025
2025 Q2 -tulosraportti
15.8.2025
2025 Q1 -tulosraportti
8.5.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q1 -tulosraportti
12 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
20.8.
Menneet tapahtumat
2026 Q1 -tulosraportti
21.5.
2025 Q4 -tulosraportti
26.3.
2025 Q3 -tulosraportti
19.11.2025
2025 Q2 -tulosraportti
15.8.2025
2025 Q1 -tulosraportti
8.5.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 11 t sitten
    ·
    11 t sitten
    ·
    We are excited to be part of the nephrology community at hashtag#ERA26 in Glasgow this week. With the updated KDIGO AKI/AKD guidelines currently in public review. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
    5 t sitten
    ·
    5 t sitten
    ·
    We know that KDIGO has issued their recommendations on each of the 18 topics. We are just waiting for the details. Now we need to put the spotlight on FDA. If they have no questions for the pre-application, and therefore give the green light for Bioporto to submit an application for the adult test. It will be interesting for us whether FDA will ensure that Bioporto receives breakthrough benefits. (just like they eventually got with the children's test) because KDIGO has given the NGAL test the strongest recommendation in some areas. If Bioporto is granted the breakthrough benefit, the following will happen. 1. Bioporto will be assigned some experts from FDA, which Bioporto can use if there are any questions. 2. They will receive quick feedback from FDA. 3. When the final application is complete and needs to be approved, it will be at the top of the pile. If Bioporto is granted the above benefit, it will be really fun to be a shareholder.
  • 1 päivä sitten
    ·
    1 päivä sitten
    ·
    There is really a lot of gold on the internet, you just have to bend down and pick it up. I have just found an overview of the topics that KDIGO's committee is currently in the process of agreeing on how the final document should be written. I have inserted a link where you can read about the different areas, What I am pleased about is that I have been right when I claimed that some areas will receive Grade 1 recommendations and others will receive lower ones. You can see that there are different color codes, which are the same colors used in the hospital world. If you click on the different topics, you can read about what diseases they are. So yes, they will be busy at Bioporto. Red: The absolute strongest recommendation (Grade 1) Blue: Strong recommendation (Grade 1 or strong Grade 2) Yellow: Minor or conditional recommendation (Grade 2) Green: Lowest recommendation / Baseline https://kdigo.org/guidelines/
    14 t sitten
    14 t sitten
    Tämä kommentti on poistettu.
    18 t sitten
    ·
    18 t sitten
    ·
    Unlike you, I have actually profited from BP. And it's probably only reasonable to ask questions, especially now that your years-long hype in BP has been completely and utterly totally misguided.
  • 1 päivä sitten
    1 päivä sitten
    Tämä julkaisu on poistettu.
    1 päivä sitten
    ·
    1 päivä sitten
    ·
    Hi 3D I have tried to do as you say. I'm getting into an almost 500-page report for the AKI area. It seems to be the one that is being prepared for publication. What's with the color codes? Once I have found the AKI report, then what?
    1 päivä sitten
    ·
    1 päivä sitten
    ·
    I have deleted this post and written a new one with a different link. try clicking the new link
  • 28.5.
    ·
    28.5.
    ·
    There must be someone who can explain "shorting" THOROUGHLY! How does it work in practice? Who offers it and why? Is there anything regarding TA, that "meets" shorting? And if so, how? Other explanations are also welcome..,: Many of us, it seems, don't have a grasp of shorting and everything it entails. Regards. Bagerbrød
    3 päivää sitten
    ·
    3 päivää sitten
    ·
    Likewise - we are still eagerly watching to see if today will push the stock up near 1.45! This is where the next "point" is, and the time interval between recent peaks COULD fit with today! I think today's closing price is exciting.
    3 päivää sitten
    ·
    3 päivää sitten
    ·
    yep - thanks 😊🐾
  • 28.5.
    ·
    28.5.
    ·
    Although it's nothing new, it's good that there are more and more small indicators of interest in the kidney area generally and Bioporto specifically. https://ugebrev.dk/life-science/bioporto-har-udviklet-et-produkt-mod-akut-nyreskade/
    3 päivää sitten · Muokattu
    ·
    3 päivää sitten · Muokattu
    ·
    Completely agree. The price has shot up 50% in 2 months and now seems to have found a natural level. No doubt many have taken that profit home, but that's actually what we want. That smaller short-term shareholders who bought under 1kr sell off, so that this group will increasingly get bigger and bigger gak. Now we will probably wait a week or 2 to get feedback from FDA regarding pre submission, and if it turns out positive as expected, then surely the price can crawl a bit higher. When/if KDIGO includes Ngal as a recommendation, then I don't think it will be unlikely we will go over 2kr.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
6--
4--
6--
1--
1 763--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt